Research Topics
| D P SteensmaSummaryAffiliation: Mayo Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Building West 10, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Mol Diagn 8:397-411; quiz 526. 2006..I also discuss diagnostic sensitivity, performance, and other practical concerns relevant to the clinical laboratorian in addition to the potential diagnostic utility of JAK2 mutation tests...
Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based surveyDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States
Leuk Res 32:691-8. 2008..Within the limitations of self-reported data, these results provide a benchmark for future interventions to improve QOL in patients with MDS...- New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophonyDavid P Steensma
Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA
J Support Oncol 5:471-3. 2007 - Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasiaDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 74:47-53. 2005..In addition, it is unclear whether patients with MDS-associated acquired alpha thalassaemia (ATMDS), a special subgroup with a very high incidence of point mutations in the ATRX gene, have an especially high incidence of RUNX1 mutations... - Northwoods elegyDavid P Steensma
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, United Kingdom
Ann Intern Med 141:573-4. 2004 - ReassuranceDavid P Steensma
Division of Hematology, Mayo Clinic, Rochester, MN, USA
J Clin Oncol 22:3196-8. 2004 - Management of anemia in patients with cancerDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Oncol Rep 6:297-304. 2004.... - Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutationsDavid P Steensma
MRC Molecula Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington, Oxford OX3 9DS, United Kingdom
Blood 103:2019-26. 2004.... 
Investment analysts and the American Society of HematologyDavid P Steensma
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Blood 112:29-33. 2008..I also propose changes in ASH policy that may help safeguard public trust as well as preserve the access of clinicians and scientists to clinically relevant data presented at the Annual Meeting...- The art of oncology: when the tumor is not the target. Don't mention itDavid P Steensma
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 26:3083-4. 2008 - Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disordersDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 139:439-42. 2007..5%) patients with myeloproliferative disorders, but in none of the acute leukaemia patients or controls. We conclude that the emergence of thalassaemic clones may be relatively common in the disordered marrow milieu of MDS... - Exacerbation of asthma by Florida "red tide" during an ocean sailing tripDavid P Steensma
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:1128-30. 2007.... - Candidate gene mutation analysis in idiopathic acquired sideroblastic anemia (refractory anemia with ringed sideroblasts)David P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 31:623-8. 2007.... - A history of the kidney in plasma cell disordersDavid P Steensma
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Contrib Nephrol 153:5-24. 2007..The kidneys are commonly injured in plasma cell dyscrasias... - MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet countDavid P Steensma
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Haematologica 91:ECR57. 2006.... - JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplainedD P Steensma
Mayo Clinic College of Medicine, Rochester, MN, USA
Leukemia 20:971-8. 2006..Janus kinase2 extrinsic regulators and other proteins in the JAK-STAT pathway should be interrogated to explain frequent STAT activation in AML... - Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancerDavid P Steensma
Mayo Clinic and Mayo Foundation, Rochester 55905, USA
J Clin Oncol 24:1079-89. 2006..To compare maintenance epoetin alfa administered once every 3 weeks with continued weekly epoetin alfa for patients with cancer-associated anemia... - Risk-based management of myelodysplastic syndromeDavid P Steensma
Mayo Clinic, Rochester, Minnesota, USA
Oncology (Williston Park) 21:43-54; discussion 57-8, 62. 2007..While many questions remain about the optimal use of newer agents, the long-standing perception of MDS as a syndrome where therapeutic nihilism is the only realistic approach is slowly beginning to change... - Luis Walter Alvarez: another "Mayo-trained" Nobel LaureateDavid P Steensma
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester MN 55905, USA
Mayo Clin Proc 81:241-4. 2006 - Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguityDavid P Steensma
Department of Medicine Hematology and Oncology, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Leuk Res 30:1227-33. 2006..Here, I discuss evidence supporting broader consideration of MDS as a form of malignant neoplasia - i.e., cancer - as well as some of the relevant practical issues... - The myelodysplastic syndromes: diagnosis and treatmentDavid P Steensma
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 81:104-30. 2006.... - Anemia in the elderly: how should we define it, when does it matter, and what can be done?David P Steensma
Division of Hematology, Mayo Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Mayo Clin Proc 82:958-66. 2007..We also outline a practical initial diagnostic approach that helps determine appropriate treatment, and we weigh therapeutic options in light of new safety concerns regarding erythropoiesis-stimulating agents... - The chronic myeloproliferative disorders: an historical perspectiveDavid P Steensma
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Curr Hematol Rep 2:221-30. 2003..This narrative review explores some of the most noteworthy episodes in those stories, from first descriptions to current understanding... - Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndromeDavid P Steensma
Division of Hematology, Department of Internal Medicine, Mayo Clinic, West 10, 200 First Street, SW, Rochester, MN 55905, USA
Leuk Res 27:775-82. 2003.... - Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasiaDavid P Steensma
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 118:813-6. 2002..Low-dose lung radiotherapy may be a useful palliative tool for patients with MMM complicated by PH... - The mosaic of myeloid neoplasia: implications for classificationDavid P Steensma
Mayo Clinic, Rochester, Minnesota, USA
Leuk Lymphoma 49:1228-9. 2008 - Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trialDavid P Steensma
Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
J Clin Oncol 27:3842-8. 2009..This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices... - Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a reviewD P Steensma
Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 42:1243-53. 2001..For patients who develop oscillatory variation in their platelet counts associated with HU use, keeping the HU dose constant may result in damping or termination of the cycles. However, this strategy is not always successful... - Myelodysplastic syndrome and pregnancy: the Mayo Clinic experienceD P Steensma
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 42:1229-34. 2001..We discuss some of the unique concerns regarding pregnant patients with MDS. As women give birth at older ages and as more young persons survive cancer, MDS and pregnancy are likely to be seen together with increasing frequency... - Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot studyDavid P Steensma
Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Blood 99:2252-4. 2002..Toxicity was mild, with injection site reactions (20%) and minor infections (10%) as the most common side effects. One patient developed reversible pancytopenia. Etanercept may be useful for palliation of constitutional symptoms in MMM... - Why me?David P Steensma
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 20:873-5. 2002 - Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromesDavid P Steensma
Mayo Clinic, Rochester, MN 55905, USA
Cancer Res 69:7518-23. 2009..These data support involvement of IER3 in the pathobiology of MDS... - Hereditary red blood cell disorders in middle eastern patientsD P Steensma
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 76:285-93. 2001..Although a detailed discussion of treatment of erythrocyte disorders is beyond the scope of this article, some general management principles are described... - "Congo" red: out of Africa?D P Steensma
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Arch Pathol Lab Med 125:250-2. 2001..Congo red is the essential histologic stain for demonstrating the presence of amyloidosis in fixed tissues. To the best of my knowledge, nothing has been written about why the stain is named "Congo.".. - Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndromeDavid P Steensma
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:2156-8. 2003..We conclude that the risk-benefit ratio of ATG in an unselected population of MDS patients may be unfavorable, and more work is needed to define the subset of patients who will respond to ATG before its widespread use can be recommended... - Myelodysplasia paranoia: iron as the new radonDavid P Steensma
Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Res 33:1158-63. 2009.... - The kiss of death: a severe allergic reaction to a shellfish induced by a good-night kissDavid P Steensma
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 78:221-2. 2003.... - "Pawn Ball Megakaryocytes": from the marvellous medici and dear Old Saint Nick to the unsanctified marrow of myelodysplasiaDavid P Steensma
Divsion of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Hematology 8:11-8. 2003..The murky history of the symbol and its significance for myelodysplasia are reviewed... - Submitting to autonomyDavid P Steensma
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:62s-63s. 2003 - Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?David P Steensma
Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 27:235-42. 2003..Continued follow-up of this heterogeneous cohort and further studies of similar patients will more clearly define the disease processes and prognosis for this constellation of laboratory findings... - Why me?David P Steensma
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:64s-66s. 2003 - The myelodysplastic syndrome(s): a perspective and review highlighting current controversiesDavid P Steensma
Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Leuk Res 27:95-120. 2003..In this narrative review, we highlight recent developments and controversies within the context of current knowledge about this mysterious and fascinating cluster of bone marrow failure states... - The narrow pathDavid P Steensma
Mayo Clinic, Rochester, MN 55905, USA
J Clin Oncol 21:57s-60s; discussion 60s. 2003 - Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasiaR A Mesa
Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Leukemia 20:1800-8. 2006..008). These results suggest that mutant JAK2 contributes to MMM pathogenesis by constitutively phosphorylating STAT3 and diminishing myeloid cell apoptosis... - Polycythemia vera: plethora, from prehistory to presentDavid P Steensma
Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
Curr Hematol Rep 4:230-4. 2005..This review traces some of the principal events in the history of polycythemia vera (PV) as a discrete clinical entity... - Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversityDavid P Steensma
Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 80:681-98. 2005.... - Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide eraShernan G Holtan
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 83:708-13. 2008..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden... - Overcoming obstacles to hospice care: an ethical examination of inertia and inactionChristopher K Daugherty
Department of Medicine, MacLean Center for Clinical Medical Ethics, the Cancer Research Center at the University of Chicago, and Vitas Hospice, Chicago, IL 60637-1470, USA
J Clin Oncol 21:42s-45s. 2003 - A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasiaRuben A Mesa
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Blood 101:2534-41. 2003..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM... - Mutations in the chromatin-associated protein ATRXRichard J Gibbons
MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
Hum Mutat 29:796-802. 2008..The truncating mutations appear to be "rescued" to some degree and so it appears likely that most if not all constitutional ATRX mutations are hypomorphs... - Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institutionRafael Santana-Davila
Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 32:407-11. 2008..We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone... - C-terminal nucleophosmin mutations are uncommon in chronic myeloid disordersJonathan S C Caudill
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 133:638-41. 2006..All other patients were NPM1-wild type in the region analysed. In conclusion, C-terminal NPM mutations are uncommon in chronic myeloid neoplasia, but if present may represent an evolving leukaemic clone... - A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndromeMaria E Nelson
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Haematologica 90:1463-70. 2005..Acquired HbH has recently been associated with mutations in an X-linked gene, ATRX, previously linked to inherited ATR-X syndrome (alpha thalassemia-retardation-X linked)... - History of multiple myelomaRobert A Kyle
Department of Medicine, Mayo Clinic, Rochester, MN, USA
Recent Results Cancer Res 183:3-23. 2011..The authors have reviewed the treatment of multiple myeloma including the novel agents, thalidomide, bortezomib and lenalidomide... - Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblastsCheng E Chee
Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
Am J Hematol 83:611-3. 2008..The current study does not support the contention that transfusional hemosiderosis is an adverse prognostic factor in "good risk" myelodysplastic syndrome... - The well-being and personal wellness promotion strategies of medical oncologists in the North Central Cancer Treatment GroupTait D Shanafelt
Department of Oncology, Mayo Clinic, Rochester, Minn, USA
Oncology 68:23-32. 2005..While much is known about oncologist distress, little is known about oncologist well-being. We set out to evaluate oncologist well-being and the personal wellness promotion strategies used by oncologists... - The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromesDavid P Steensma
Mayo Clinic and Mayo Clinic College of Medicine, Rochester MN 55905, USA
Blood 106:1207-9. 2005..The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders... - Cytogenetic and molecular genetic aspects of essential thrombocythemiaDavid P Steensma
Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn. 55905, USA
Acta Haematol 108:55-65. 2002..In the future, global analysis of gene expression patterns may help overcome diagnostic dilemmas, refine disease classification, and lead to an improved understanding of the pathogenesis of ET... - Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemiaAyalew Tefferi
Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 131:166-71. 2005..However, compared with the PRV-1 assay, mutation screening for JAK2(V617F) displayed greater accuracy in distinguishing PV from SP... - The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosisRuben A Mesa
Mayo Clinic, Rochester, MN, USA
Leuk Res 33:1199-203. 2009..The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials... - Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does notAyalew Tefferi
Division of Hematology Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 84:265-7. 2009..003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value... - The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlatesAyalew Tefferi
Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Br J Haematol 131:320-8. 2005.... - Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasiaAyalew Tefferi
Mayo Clinic, Rochester, MN 55905, USA
Blood 99:3854-6. 2002..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit... - Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experienceCarrie A Thompson
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Br J Haematol 135:405-7. 2006..However, treatment-related morbidity was high, with frequent infectious complications... - Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysisPaul J Thurmes
Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Eur J Haematol 77:57-60. 2006..The purpose of this study was to use JAK2 V617F analysis to re-evaluate the validity of elevated Epo levels as a PV-exclusion criterion in patients with hepatic vein thrombosis [Budd-Chiari syndrome (BCS)]... - Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative casesRafael Santana-Davila
Division of Hematology, Mayo Clinic, Rochester, MN, USA
Leuk Res 32:1927-30. 2008..When used, lenalidomide therapy induced hematological and cytogenetic remissions in del(5q)-positive PMF. The current study identifies PMF as another del(5q)-associated myeloid malignancy with characteristic megakaryocyte morphology... - A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and deathD P Steensma
Mayo Clinic, Rochester, MN 55905, USA
Blood 97:2522-3. 2001..0001). These findings suggest that a high PCLI in patients with apparently stable, plateau phase MM is an adverse parameter that may predict a short time to disease progression and death... - Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndromeA Tefferi
Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 25:183-5. 2001..None of the patients experienced a complete or partial response in anemia or other cytopenias. We conclude that amifostine alone or in combination with EPO has limited therapeutic activity in MDS... - Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndromeDavid P Steensma
Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Headington Oxford OX3 9DU, United Kingdom
Blood 103:1518-20. 2004.... - Anemia or low hemoglobin levels preceding Parkinson disease: a case-control studyR Savica
Department of Neurology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Neurology 73:1381-7. 2009..Thus, we investigated the association of anemia with the subsequent risk of PD using a case-control study design... - MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patientsAnimesh D Pardanani
Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Blood 108:3472-6. 2006..Furthermore, MPL mutations may occur concurrently with the JAK2V617F mutation, suggesting that these alleles may have functional complementation in myeloproliferative disease... - Overcoming obstacles to hospice care: an ethical examination of inertia and inactionChristopher K Daugherty
Department of Medicine, MacLean Center for Clinical Medical Ethics, the Cancer Research Center at the University of Chicago, IL, USA
J Clin Oncol 20:2752-5. 2002 - On the TRAIL of a new therapy for leukemiaS H Kaufmann
Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
Leukemia 19:2195-202. 2005..Collectively, the reviewed studies not only illustrate the potential therapeutic usefulness of TRAIL and the agonistic antibodies, but also highlight the need for additional preclinical evaluation of these agents... - Epoetin alfa and darbepoetin alfa go head to headDavid P Steensma
J Clin Oncol 24:2233-6. 2006 - A novel mutation in the last exon of ATRX in a patient with alpha-thalassemia myelodysplastic syndromeDaniel B Costa
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Eur J Haematol 76:432-5, 453. 2006..R2407X). This case provides further evidence for a link between ATRX mutations and ATMDS, and suggests a possible role for the conserved Q-box element in ATRX function... - Sir Charles Sherrington--"The William Harvey of the nervous system"Marc A Shampo
Mayo Clin Proc 80:1266. 2005 - Is anemia of cancer different from chemotherapy-induced anemia?David P Steensma
J Clin Oncol 26:1022-4. 2008 - Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agentsDavid P Steensma
Am J Hematol 83:693-4. 2008 - Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylateRuben A Mesa
Br J Haematol 123:366-7. 2003